FADY BOULES: Open Payments
NPI 1639541022 · REDLANDS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,509 in 41 payments from 9 companies in 2025. Trend: 2023 $1,109 · 2024 $1,415 · 2025 $1,509
Food & beverage: $1,509
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $537 |
| Otsuka America Pharmaceutical, Inc. | 5 | $275 |
| Teva Pharmaceuticals USA, Inc. | 4 | $173 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $146 |
| E.R. Squibb & Sons, L.L.C. | 1 | $126 |
| Alkermes, Inc. | 1 | $122 |
| Axsome Therapeutics, Inc. | 1 | $112 |
| Lundbeck LLC | 1 | $15 |
| Corium, LLC | 1 | $5 |
Products named: VRAYLAR, REXULTI, UZEDY, CAPLYTA, COBENFY, LYBALVI, Auvelity, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
